Cameron BA - Search Results

1

Chang CC, Crane M, Zhou J, Mina M, Post JJ, Cameron BA, Lloyd AR, Jaworowski A, French MA, Lewin SR. Chang CC, et al. Among authors: cameron ba. Immunol Rev. 2013 Jul;254(1):114-42. doi: 10.1111/imr.12063. Immunol Rev. 2013. PMID: 23772618 Free PMC article. Review.

2

Alterations in immune function are associated with liver enzyme elevation in HIV and HCV co-infection after commencement of combination antiretroviral therapy.

Cameron BA, Emerson CR, Workman C, Kelly MD, Lloyd AR, Post JJ. Cameron BA, et al. J Clin Immunol. 2011 Dec;31(6):1079-83. doi: 10.1007/s10875-011-9587-6. Epub 2011 Sep 20. J Clin Immunol. 2011. PMID: 21932111

3

Occult infection with hepatitis C virus: friend or foe?

Sugden PB, Cameron B, Bull R, White PA, Lloyd AR. Sugden PB, et al. Immunol Cell Biol. 2012 Sep;90(8):763-73. doi: 10.1038/icb.2012.20. Epub 2012 May 1. Immunol Cell Biol. 2012. PMID: 22546735 Review.

4

Impaired hepatitis C virus (HCV)-specific interferon-γ responses in individuals with HIV who acquire HCV infection: correlation with CD4(+) T-cell counts.

Flynn JK, Dore GJ, Matthews G, Hellard M, Yeung B, Rawlinson WD, White PA, Kaldor JM, Lloyd AR, Ffrench RA; ATAHC Study Group. Flynn JK, et al. J Infect Dis. 2012 Nov 15;206(10):1568-76. doi: 10.1093/infdis/jis544. Epub 2012 Sep 4. J Infect Dis. 2012. PMID: 22949308 Free PMC article.

5

Protection against hepatitis C infection via NK cells in highly-exposed uninfected injecting drug users.

Sugden PB, Cameron B, Mina M, Lloyd AR; HITS investigators. Sugden PB, et al. J Hepatol. 2014 Oct;61(4):738-45. doi: 10.1016/j.jhep.2014.05.013. Epub 2014 May 15. J Hepatol. 2014. PMID: 24845613

6

Resistance to hepatitis C virus: potential genetic and immunological determinants.

Mina MM, Luciani F, Cameron B, Bull RA, Beard MR, Booth D, Lloyd AR. Mina MM, et al. Lancet Infect Dis. 2015 Apr;15(4):451-60. doi: 10.1016/S1473-3099(14)70965-X. Epub 2015 Feb 19. Lancet Infect Dis. 2015. PMID: 25703062 Review.

7

Natural killer cells in highly exposed hepatitis C-seronegative injecting drug users.

Mina MM, Cameron B, Luciani F, Vollmer-Conna U, Lloyd AR; HITS-p investigators. Mina MM, et al. J Viral Hepat. 2016 Jun;23(6):464-72. doi: 10.1111/jvh.12511. Epub 2016 Feb 1. J Viral Hepat. 2016. PMID: 26833632

8

Peripheral blood gene expression in postinfective fatigue syndrome following from three different triggering infections.

Galbraith S, Cameron B, Li H, Lau D, Vollmer-Conna U, Lloyd AR. Galbraith S, et al. J Infect Dis. 2011 Nov 15;204(10):1632-40. doi: 10.1093/infdis/jir612. Epub 2011 Sep 29. J Infect Dis. 2011. PMID: 21964398

9

Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment.

Flynn JK, Dore GJ, Hellard M, Yeung B, Rawlinson WD, White PA, Kaldor JM, Lloyd AR, Ffrench RA; ATAHC Study Group. Flynn JK, et al. J Gastroenterol Hepatol. 2013 Nov;28(11):1770-81. doi: 10.1111/jgh.12265. J Gastroenterol Hepatol. 2013. PMID: 23663030 Free PMC article.

10

Transmitted/Founder Viruses Rapidly Escape from CD8+ T Cell Responses in Acute Hepatitis C Virus Infection.

Bull RA, Leung P, Gaudieri S, Deshpande P, Cameron B, Walker M, Chopra A, Lloyd AR, Luciani F. Bull RA, et al. J Virol. 2015 May;89(10):5478-90. doi: 10.1128/JVI.03717-14. Epub 2015 Mar 4. J Virol. 2015. PMID: 25740982 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page